Global Fabry Disease Market

Fabry Disease Comprehensive Study by Application (Child, Women, Men), Treatment (Enzyme Replacement Therapy, Gene Therapy, Analgesics, Anticonvulsants, NSAIDs) Players and Region - Global Market Outlook to 2030

Fabry Disease Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 8.1%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Fabry Disease
Fabry Disease is an X-linked genetic disease caused by a deficiency of the enzyme αgalactosidase A (α-Gal A) in the body. The enzyme α-Gal A’s function is to break down fatty element called globotriaosylceramide (or GL3). When α-Gal A is absent, GL3 builds up in the blood vessel walls in the body. As the unusual storage of GL3 increases with time, the body’s blood vessels become narrowed, which leads to decreased blood flow and undernourishment of the tissues. This abnormal process occurs in blood vessels throughout the body, particularly those blood vessels in the skin, kidneys, heart, brain and nervous system. The early symptoms of Fabry disease such as decreased sweating, heat intolerance, proteinuria, a reddish-purple skin rash, severe pains in the hands and feet, hearing loss, chronic fatigue, and gastrointestinal issues, generally start in childhood. Fabry disease symptoms affect both women and men.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR8.1%


New and existing market players are coming up with better treatment approaches. The companies are exploring the market in new regions by adopting expansions, investments, new launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisition to avail competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Fabry Disease market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Bristol-Myers Squibb Company (United States), AbbVie Inc. (United States), Teva pharmaceutical Industries Ltd. (Israel), Pfizer Inc. (United States), Takeda Pharmaceutical Co. Ltd. (Japan), Sanofi-Aventis LLC (United States), GlaxoSmithKline plc (United Kingdom), Shire (United States), Protalix BioTherapeutics (Israel), Green Cross Corp. (South Korea) and Idorsia Pharmaceuticals Ltd (Switzerland) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Fabry Disease market by , Application (Child, Women and Men) and Region.



On the basis of geography, the market of Fabry Disease has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Enzyme Replacement Therapy will boost the Fabry Disease market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Regulatory Assistance in Emerging Countries

Market Growth Drivers:
Growing Acceptance of Advanced Technologies in Research Practices and Special Provisions for Orphan Drugs

Challenges:
Technological Limitations for the Treatment

Restraints:
Lack of Awareness about Advancements in Genetic Sciences and Complications in Physiological Systems

Opportunities:
Increasing Investment on Healthcare Sector in Developing Countries and Special Incentives in the Form of Funding to Vendors to Conduct Research in Fabry Disease

Market Leaders and their expansionary development strategies
In August 2023, Sanofi Genzyme launched Fabrazyme (agalsidase beta) Infused Reconstituted Powder for Injection, a new formulation of their existing enzyme replacement therapy for Fabry Disease. This new formulation requires a shorter infusion time compared to the previous liquid formulation.
In September 2023, Amicus Therapeutics received FDA approval for Galafold (migalastat hydrochloride) capsules, a new oral treatment option for Fabry Disease patients with amenable GLA mutations. This was the first oral therapy approved for Fabry Disease in the US.
On 10 August 2018 The U.S. Food and Drug Administration have approved Galafold (migalastat), the first oral medication for the treatment of adults with Fabry disease.

Key Target Audience
Suppliers of Pharmaceuticals, Wholesalers, Distributors and Retailers of Pharmaceuticals, Healthcare Industry, Research Firms and Governmental Bodies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Child
  • Women
  • Men
By Treatment
  • Enzyme Replacement Therapy
  • Gene Therapy
  • Analgesics
  • Anticonvulsants
  • NSAIDs

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Acceptance of Advanced Technologies in Research Practices
      • 3.2.2. Special Provisions for Orphan Drugs
    • 3.3. Market Challenges
      • 3.3.1. Technological Limitations for the Treatment
    • 3.4. Market Trends
      • 3.4.1. Increasing Regulatory Assistance in Emerging Countries
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Fabry Disease, by Application, Treatment and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Fabry Disease (Value)
      • 5.2.1. Global Fabry Disease by: Application (Value)
        • 5.2.1.1. Child
        • 5.2.1.2. Women
        • 5.2.1.3. Men
      • 5.2.2. Global Fabry Disease by: Treatment (Value)
        • 5.2.2.1. Enzyme Replacement Therapy
        • 5.2.2.2. Gene Therapy
        • 5.2.2.3. Analgesics
        • 5.2.2.4. Anticonvulsants
        • 5.2.2.5. NSAIDs
      • 5.2.3. Global Fabry Disease Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Fabry Disease (Price)
  • 6. Fabry Disease: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristol-Myers Squibb Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AbbVie Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva pharmaceutical Industries Ltd. (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Takeda Pharmaceutical Co. Ltd. (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi-Aventis LLC (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline plc (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Shire (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Protalix BioTherapeutics (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Green Cross Corp. (South Korea)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Idorsia Pharmaceuticals Ltd (Switzerland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Fabry Disease Sale, by Application, Treatment and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Fabry Disease (Value)
      • 7.2.1. Global Fabry Disease by: Application (Value)
        • 7.2.1.1. Child
        • 7.2.1.2. Women
        • 7.2.1.3. Men
      • 7.2.2. Global Fabry Disease by: Treatment (Value)
        • 7.2.2.1. Enzyme Replacement Therapy
        • 7.2.2.2. Gene Therapy
        • 7.2.2.3. Analgesics
        • 7.2.2.4. Anticonvulsants
        • 7.2.2.5. NSAIDs
      • 7.2.3. Global Fabry Disease Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Fabry Disease (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Fabry Disease: by Application(USD Million)
  • Table 2. Fabry Disease Child , by Region USD Million (2018-2023)
  • Table 3. Fabry Disease Women , by Region USD Million (2018-2023)
  • Table 4. Fabry Disease Men , by Region USD Million (2018-2023)
  • Table 5. Fabry Disease: by Treatment(USD Million)
  • Table 6. Fabry Disease Enzyme Replacement Therapy , by Region USD Million (2018-2023)
  • Table 7. Fabry Disease Gene Therapy , by Region USD Million (2018-2023)
  • Table 8. Fabry Disease Analgesics , by Region USD Million (2018-2023)
  • Table 9. Fabry Disease Anticonvulsants , by Region USD Million (2018-2023)
  • Table 10. Fabry Disease NSAIDs , by Region USD Million (2018-2023)
  • Table 11. South America Fabry Disease, by Country USD Million (2018-2023)
  • Table 12. South America Fabry Disease, by Application USD Million (2018-2023)
  • Table 13. South America Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 14. Brazil Fabry Disease, by Application USD Million (2018-2023)
  • Table 15. Brazil Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 16. Argentina Fabry Disease, by Application USD Million (2018-2023)
  • Table 17. Argentina Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 18. Rest of South America Fabry Disease, by Application USD Million (2018-2023)
  • Table 19. Rest of South America Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 20. Asia Pacific Fabry Disease, by Country USD Million (2018-2023)
  • Table 21. Asia Pacific Fabry Disease, by Application USD Million (2018-2023)
  • Table 22. Asia Pacific Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 23. China Fabry Disease, by Application USD Million (2018-2023)
  • Table 24. China Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 25. Japan Fabry Disease, by Application USD Million (2018-2023)
  • Table 26. Japan Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 27. India Fabry Disease, by Application USD Million (2018-2023)
  • Table 28. India Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 29. South Korea Fabry Disease, by Application USD Million (2018-2023)
  • Table 30. South Korea Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 31. Taiwan Fabry Disease, by Application USD Million (2018-2023)
  • Table 32. Taiwan Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 33. Australia Fabry Disease, by Application USD Million (2018-2023)
  • Table 34. Australia Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 35. Rest of Asia-Pacific Fabry Disease, by Application USD Million (2018-2023)
  • Table 36. Rest of Asia-Pacific Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 37. Europe Fabry Disease, by Country USD Million (2018-2023)
  • Table 38. Europe Fabry Disease, by Application USD Million (2018-2023)
  • Table 39. Europe Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 40. Germany Fabry Disease, by Application USD Million (2018-2023)
  • Table 41. Germany Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 42. France Fabry Disease, by Application USD Million (2018-2023)
  • Table 43. France Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 44. Italy Fabry Disease, by Application USD Million (2018-2023)
  • Table 45. Italy Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 46. United Kingdom Fabry Disease, by Application USD Million (2018-2023)
  • Table 47. United Kingdom Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 48. Netherlands Fabry Disease, by Application USD Million (2018-2023)
  • Table 49. Netherlands Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 50. Rest of Europe Fabry Disease, by Application USD Million (2018-2023)
  • Table 51. Rest of Europe Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 52. MEA Fabry Disease, by Country USD Million (2018-2023)
  • Table 53. MEA Fabry Disease, by Application USD Million (2018-2023)
  • Table 54. MEA Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 55. Middle East Fabry Disease, by Application USD Million (2018-2023)
  • Table 56. Middle East Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 57. Africa Fabry Disease, by Application USD Million (2018-2023)
  • Table 58. Africa Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 59. North America Fabry Disease, by Country USD Million (2018-2023)
  • Table 60. North America Fabry Disease, by Application USD Million (2018-2023)
  • Table 61. North America Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 62. United States Fabry Disease, by Application USD Million (2018-2023)
  • Table 63. United States Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 64. Canada Fabry Disease, by Application USD Million (2018-2023)
  • Table 65. Canada Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 66. Mexico Fabry Disease, by Application USD Million (2018-2023)
  • Table 67. Mexico Fabry Disease, by Treatment USD Million (2018-2023)
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Fabry Disease: by Application(USD Million)
  • Table 80. Fabry Disease Child , by Region USD Million (2025-2030)
  • Table 81. Fabry Disease Women , by Region USD Million (2025-2030)
  • Table 82. Fabry Disease Men , by Region USD Million (2025-2030)
  • Table 83. Fabry Disease: by Treatment(USD Million)
  • Table 84. Fabry Disease Enzyme Replacement Therapy , by Region USD Million (2025-2030)
  • Table 85. Fabry Disease Gene Therapy , by Region USD Million (2025-2030)
  • Table 86. Fabry Disease Analgesics , by Region USD Million (2025-2030)
  • Table 87. Fabry Disease Anticonvulsants , by Region USD Million (2025-2030)
  • Table 88. Fabry Disease NSAIDs , by Region USD Million (2025-2030)
  • Table 89. South America Fabry Disease, by Country USD Million (2025-2030)
  • Table 90. South America Fabry Disease, by Application USD Million (2025-2030)
  • Table 91. South America Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 92. Brazil Fabry Disease, by Application USD Million (2025-2030)
  • Table 93. Brazil Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 94. Argentina Fabry Disease, by Application USD Million (2025-2030)
  • Table 95. Argentina Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 96. Rest of South America Fabry Disease, by Application USD Million (2025-2030)
  • Table 97. Rest of South America Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 98. Asia Pacific Fabry Disease, by Country USD Million (2025-2030)
  • Table 99. Asia Pacific Fabry Disease, by Application USD Million (2025-2030)
  • Table 100. Asia Pacific Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 101. China Fabry Disease, by Application USD Million (2025-2030)
  • Table 102. China Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 103. Japan Fabry Disease, by Application USD Million (2025-2030)
  • Table 104. Japan Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 105. India Fabry Disease, by Application USD Million (2025-2030)
  • Table 106. India Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 107. South Korea Fabry Disease, by Application USD Million (2025-2030)
  • Table 108. South Korea Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 109. Taiwan Fabry Disease, by Application USD Million (2025-2030)
  • Table 110. Taiwan Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 111. Australia Fabry Disease, by Application USD Million (2025-2030)
  • Table 112. Australia Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 113. Rest of Asia-Pacific Fabry Disease, by Application USD Million (2025-2030)
  • Table 114. Rest of Asia-Pacific Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 115. Europe Fabry Disease, by Country USD Million (2025-2030)
  • Table 116. Europe Fabry Disease, by Application USD Million (2025-2030)
  • Table 117. Europe Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 118. Germany Fabry Disease, by Application USD Million (2025-2030)
  • Table 119. Germany Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 120. France Fabry Disease, by Application USD Million (2025-2030)
  • Table 121. France Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 122. Italy Fabry Disease, by Application USD Million (2025-2030)
  • Table 123. Italy Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 124. United Kingdom Fabry Disease, by Application USD Million (2025-2030)
  • Table 125. United Kingdom Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 126. Netherlands Fabry Disease, by Application USD Million (2025-2030)
  • Table 127. Netherlands Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 128. Rest of Europe Fabry Disease, by Application USD Million (2025-2030)
  • Table 129. Rest of Europe Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 130. MEA Fabry Disease, by Country USD Million (2025-2030)
  • Table 131. MEA Fabry Disease, by Application USD Million (2025-2030)
  • Table 132. MEA Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 133. Middle East Fabry Disease, by Application USD Million (2025-2030)
  • Table 134. Middle East Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 135. Africa Fabry Disease, by Application USD Million (2025-2030)
  • Table 136. Africa Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 137. North America Fabry Disease, by Country USD Million (2025-2030)
  • Table 138. North America Fabry Disease, by Application USD Million (2025-2030)
  • Table 139. North America Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 140. United States Fabry Disease, by Application USD Million (2025-2030)
  • Table 141. United States Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 142. Canada Fabry Disease, by Application USD Million (2025-2030)
  • Table 143. Canada Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 144. Mexico Fabry Disease, by Application USD Million (2025-2030)
  • Table 145. Mexico Fabry Disease, by Treatment USD Million (2025-2030)
  • Table 146. Research Programs/Design for This Report
  • Table 147. Key Data Information from Secondary Sources
  • Table 148. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Fabry Disease: by Application USD Million (2018-2023)
  • Figure 5. Global Fabry Disease: by Treatment USD Million (2018-2023)
  • Figure 6. South America Fabry Disease Share (%), by Country
  • Figure 7. Asia Pacific Fabry Disease Share (%), by Country
  • Figure 8. Europe Fabry Disease Share (%), by Country
  • Figure 9. MEA Fabry Disease Share (%), by Country
  • Figure 10. North America Fabry Disease Share (%), by Country
  • Figure 11. Global Fabry Disease share by Players 2023 (%)
  • Figure 12. Global Fabry Disease share by Players (Top 3) 2023(%)
  • Figure 13. Global Fabry Disease share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 16. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2023
  • Figure 17. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. AbbVie Inc. (United States) Revenue: by Geography 2023
  • Figure 19. Teva pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 20. Teva pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 21. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 23. Takeda Pharmaceutical Co. Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 24. Takeda Pharmaceutical Co. Ltd. (Japan) Revenue: by Geography 2023
  • Figure 25. Sanofi-Aventis LLC (United States) Revenue, Net Income and Gross profit
  • Figure 26. Sanofi-Aventis LLC (United States) Revenue: by Geography 2023
  • Figure 27. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 29. Shire (United States) Revenue, Net Income and Gross profit
  • Figure 30. Shire (United States) Revenue: by Geography 2023
  • Figure 31. Protalix BioTherapeutics (Israel) Revenue, Net Income and Gross profit
  • Figure 32. Protalix BioTherapeutics (Israel) Revenue: by Geography 2023
  • Figure 33. Green Cross Corp. (South Korea) Revenue, Net Income and Gross profit
  • Figure 34. Green Cross Corp. (South Korea) Revenue: by Geography 2023
  • Figure 35. Idorsia Pharmaceuticals Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Idorsia Pharmaceuticals Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 37. Global Fabry Disease: by Application USD Million (2025-2030)
  • Figure 38. Global Fabry Disease: by Treatment USD Million (2025-2030)
  • Figure 39. South America Fabry Disease Share (%), by Country
  • Figure 40. Asia Pacific Fabry Disease Share (%), by Country
  • Figure 41. Europe Fabry Disease Share (%), by Country
  • Figure 42. MEA Fabry Disease Share (%), by Country
  • Figure 43. North America Fabry Disease Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bristol-Myers Squibb Company (United States)
  • AbbVie Inc. (United States)
  • Teva pharmaceutical Industries Ltd. (Israel)
  • Pfizer Inc. (United States)
  • Takeda Pharmaceutical Co. Ltd. (Japan)
  • Sanofi-Aventis LLC (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Shire (United States)
  • Protalix BioTherapeutics (Israel)
  • Green Cross Corp. (South Korea)
  • Idorsia Pharmaceuticals Ltd (Switzerland)
Select User Access Type

Key Highlights of Report


Jan 2024 240 Pages 74 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Fabry Disease Market Quantitative research analysis
Global Fabry Disease Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Bristol-Myers Squibb Company (United States), AbbVie Inc. (United States), Teva pharmaceutical Industries Ltd. (Israel), Pfizer Inc. (United States), Takeda Pharmaceutical Co. Ltd. (Japan), Sanofi-Aventis LLC (United States), GlaxoSmithKline plc (United Kingdom), Shire (United States), Protalix BioTherapeutics (Israel), Green Cross Corp. (South Korea) and Idorsia Pharmaceuticals Ltd (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Regulatory Assistance in Emerging Countries" is seen as one of major influencing trends for Fabry Disease Market during projected period 2023-2030.
The Fabry Disease market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Fabry Disease Market Report?

Have a Query? Click Here

Other Related Reports

Combination Therapy Drug Comprehensive Study by Type (Diammonium Glycyrrhizinate, Interferon and Nucleoside Drugs, Targeted Therapies Drugs), Application (Cancer, Cardiovascular Disease, Immune Disea...
$ 3450
Healthcare Adhesive Tape Comprehensive Study by Application (Wound Dressing, Secure Iv Lines, Ostomy Seal, Splint, Bandages, Others), Technology (Water-Based, Solvent-Based, Hot-Melt-Based), Material...
$ 3650
Acute Migraine Drugs Comprehensive Study by Type (Nonsteroidal Anti-Inflammatory Drugs, Triptans, Dihydroergotamine, Nonspecific Migraine Medications, Analgesics), Application (Hospitals, Clinics, Ho...
$ 3650
Tardive Dyskinesia Comprehensive Study by Application (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers), Treatment (Dopamine-Depleting Medications, GABA Receptor Agonist Medications, Antic...
$ 3450
Chemotherapy-Induced Nausea and Vomiting (CINV) Comprehensive Study by Type (CINV, PONV), Application (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers), Patient Pool Type (Aloxi, Kytril, E...
$ 3450
Erythropoietin Drugs Comprehensive Study by Type (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), Application (Anemia (Cancer and HIV treatment), Kidney Disorders (ESRD and Dialysis), Others (...
$ 3450